Cipla Limited has said that it has received final approval for its Abbreviated New Drug Application (ANDA) for Efavirenz Tablets 600mg from the United States Food and Drug Administration (US FDA). Cipla’s Efavirenz Tablets 600mg is AB-rated generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s, Sustiva®. It is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.
According to IQVIA (IMS Health), Sustiva® and its generic equivalents had US sales of approximately $105M for the 12-month period ending April 2018. The product is available for shipping immediately. Meanwhile, shares of the company were trading at Rs 617 apiece, up 2.45 per cent from the previous close at 09:30 hours on BSE.
Best services for customers with full technical support make your Financial Trading more easy click here to subscribe us for free >> Nifty Market Tips
No comments:
Post a Comment